185 related articles for article (PubMed ID: 37682177)
21. Solute carrier-related signature for assessing prognosis and immunity in patients with clear-cell renal cell carcinoma.
Bao W; Han Q; Guan X; Wang Z; Gu M
Oncol Res; 2023; 31(2):181-192. PubMed ID: 37304236
[TBL] [Abstract][Full Text] [Related]
22. Tumor-suppressive effects of microRNA-181d-5p on non-small-cell lung cancer through the CDKN3-mediated Akt signaling pathway in vivo and in vitro.
Gao LM; Zheng Y; Wang P; Zheng L; Zhang WL; Di Y; Chen LL; Yin XB; Tian Q; Shi SS; Xu SF
Am J Physiol Lung Cell Mol Physiol; 2019 May; 316(5):L918-L933. PubMed ID: 30628487
[TBL] [Abstract][Full Text] [Related]
23. POLD1 as a Prognostic Biomarker Correlated with Cell Proliferation and Immune Infiltration in Clear Cell Renal Cell Carcinoma.
Tian J; Cheng C; Gao J; Fu G; Xu Z; Chen X; Wu Y; Jin B
Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047824
[TBL] [Abstract][Full Text] [Related]
24. Construction of an immune-related prognostic model by exploring the tumor microenvironment of clear cell renal cell carcinoma.
He J; Zhong Y; Sun Y; Xie C; Yu T
Anal Biochem; 2022 Apr; 643():114567. PubMed ID: 35122734
[TBL] [Abstract][Full Text] [Related]
25. The Role of Serine Peptidase Inhibitor Kazal Type 13 (SPINK13) as a Clinicopathological and Prognostic Biomarker in Patients with Clear Cell Renal Cell Carcinoma.
Xu WH; Shi SN; Wang J; Xu Y; Tian X; Wan FN; Cao DL; Qu YY; Zhang HL; Ye DW
Med Sci Monit; 2019 Dec; 25():9458-9470. PubMed ID: 31825950
[TBL] [Abstract][Full Text] [Related]
26. DKC1 serves as a potential prognostic biomarker for human clear cell renal cell carcinoma and promotes its proliferation, migration and invasion via the NF‑κB pathway.
Zhang M; Pan Y; Jiang R; Hou P; Shan H; Chen F; Jiang T; Bai J; Zheng J
Oncol Rep; 2018 Aug; 40(2):968-978. PubMed ID: 29901172
[TBL] [Abstract][Full Text] [Related]
27. Senescence gene expression in clear cell renal cell carcinoma: Role of tumor immune microenvironment and senescence-associated survival prediction.
Wu Y; Li X
Medicine (Baltimore); 2023 Oct; 102(40):e35222. PubMed ID: 37800815
[TBL] [Abstract][Full Text] [Related]
28. Cyclin-Dependent Kinase Inhibitor 3 Promotes Cancer Cell Proliferation and Tumorigenesis in Nasopharyngeal Carcinoma by Targeting p27.
Wang H; Chen H; Zhou H; Yu W; Lu Z
Oncol Res; 2017 Nov; 25(9):1431-1440. PubMed ID: 28109073
[TBL] [Abstract][Full Text] [Related]
29. Prediction of overall survival based upon a new ferroptosis-related gene signature in patients with clear cell renal cell carcinoma.
Sun Z; Li T; Xiao C; Zou S; Zhang M; Zhang Q; Wang Z; Zhan H; Wang H
World J Surg Oncol; 2022 Apr; 20(1):120. PubMed ID: 35422048
[TBL] [Abstract][Full Text] [Related]
30. Downregulation of
Wang T; Xie F; Li YH; Liang B
Future Oncol; 2021 Dec; 17(36):5033-5044. PubMed ID: 34704468
[TBL] [Abstract][Full Text] [Related]
31. Cyclin-dependent kinase inhibitor 3 (CDKN3) novel cell cycle computational network between human non-malignancy associated hepatitis/cirrhosis and hepatocellular carcinoma (HCC) transformation.
Wang L; Sun L; Huang J; Jiang M
Cell Prolif; 2011 Jun; 44(3):291-9. PubMed ID: 21535270
[TBL] [Abstract][Full Text] [Related]
32. USP31 serves as a potential biomarker for predicting prognosis and immune responses for clear cell renal cell carcinoma via single-cell and bulk RNA-sequencing.
Yu Y; Chen G; Jiang C; Guo T; Tang H; Yuan Z; Wang Y; Tan X; Chen J; Zhang E; Wang X
J Gene Med; 2024 Jan; 26(1):e3594. PubMed ID: 37699648
[TBL] [Abstract][Full Text] [Related]
33. Establishment and validation of a novel anoikis-related prognostic signature of clear cell renal cell carcinoma.
Liu Y; Shi Z; Zheng J; Zheng Z; Sun H; Xuan Z; Bai Y; Fu M; Du Y; Shao C
Front Immunol; 2023; 14():1171883. PubMed ID: 37056778
[TBL] [Abstract][Full Text] [Related]
34. Comprehensive analyses of A 12-metabolism-associated gene signature and its connection with tumor metastases in clear cell renal cell carcinoma.
Tan D; Miao D; Zhao C; Shi J; Lv Q; Xiong Z; Yang H; Zhang X
BMC Cancer; 2023 Mar; 23(1):264. PubMed ID: 36949462
[TBL] [Abstract][Full Text] [Related]
35. Cuproptosis-related gene
Wang T; Liu Y; Li Q; Luo Y; Liu D; Li B
Front Immunol; 2022; 13():999823. PubMed ID: 36225932
[TBL] [Abstract][Full Text] [Related]
36. NUF2 is correlated with a poor prognosis and immune infiltration in clear cell renal cell carcinoma.
Zheng B; Wang S; Yuan X; Zhang J; Shen Z; Ge C
BMC Urol; 2023 May; 23(1):82. PubMed ID: 37138262
[TBL] [Abstract][Full Text] [Related]
37. The value of EYA1/3/4 in clear cell renal cell carcinoma: a study from multiple databases.
Liu T; Nie J; Zhang X; Deng X; Fu B
Sci Rep; 2023 May; 13(1):7442. PubMed ID: 37156847
[TBL] [Abstract][Full Text] [Related]
38. Identification of C3 and FN1 as potential biomarkers associated with progression and prognosis for clear cell renal cell carcinoma.
Dong Y; Ma WM; Yang W; Hao L; Zhang SQ; Fang K; Hu CH; Zhang QJ; Shi ZD; Zhang WD; Fan T; Xia T; Han CH
BMC Cancer; 2021 Oct; 21(1):1135. PubMed ID: 34688260
[TBL] [Abstract][Full Text] [Related]
39. Identification and verification of a novel anoikis-related gene signature with prognostic significance in clear cell renal cell carcinoma.
He Z; Gu Y; Yang H; Fu Q; Zhao M; Xie Y; Liu Y; Du W
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11661-11678. PubMed ID: 37402968
[TBL] [Abstract][Full Text] [Related]
40. ADAM metallopeptidase domain 12 overexpression correlates with prognosis and immune cell infiltration in clear cell renal cell carcinoma.
Gao J; Yang D; Xu H; Yang K; Ma J; Xia J; Pan X
Bioengineered; 2022 Feb; 13(2):2412-2429. PubMed ID: 35094638
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
